Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 14,870 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil Dahiyat sold 14,870 shares of Xencor stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $167,287.50. Following the completion of the transaction, the chief executive officer directly owned 552,922 shares of the company’s stock, valued at approximately $6,220,372.50. This represents a 2.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Xencor Stock Up 4.9%

Shares of NASDAQ:XNCR opened at $11.87 on Tuesday. The company’s fifty day moving average is $12.73 and its two-hundred day moving average is $13.03. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $18.69. The stock has a market capitalization of $870.55 million, a price-to-earnings ratio of -9.57 and a beta of 0.95.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The business had revenue of $28.24 million during the quarter, compared to analyst estimates of $29.97 million. During the same period in the previous year, the business posted ($0.62) EPS. The company’s quarterly revenue was down 46.6% on a year-over-year basis. Equities analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.

Xencor News Summary

Here are the key news stories impacting Xencor this week:

• Negative Sentiment: Xencor and Genentech have agreed to end their protein-therapeutics collaboration. This removes a strategic partner that could have provided development resources, milestone and/or royalty payments tied to the collaboration and could delay or change the path-to-market for affected programs; however, termination may return rights to Xencor and let the company seek new partners or advance programs independently. Xencor, Genentech to End Protein Therapeutics Collaboration
• Negative Sentiment: Multiple insider sales by senior Xencor executives were disclosed this week: CEO Bassil Dahiyat sold 14,870 shares on March 5 and 6,606 shares on March 6 (total 21,476 shares), SVP Celia Eckert sold 5,011 shares across March 5–6, and VP John Desjarlais sold 6,620 shares across March 5–6. Aggregate proceeds reported are in the low six-figure range per trade. These clustered sales by top executives can be read negatively by the market (profit-taking or reduced insider conviction), unless part of pre-planned 10b5‑1 arrangements (no such plan was disclosed in these notices). Relevant SEC filings: CEO Form 4(s) SVP Form 4(s) VP Form 4(s)

Wall Street Analyst Weigh In

XNCR has been the subject of several recent research reports. Barclays upped their target price on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a report on Monday, December 29th. Truist Financial started coverage on Xencor in a research report on Monday, November 24th. They set a “buy” rating and a $29.00 price objective for the company. Finally, Wall Street Zen downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Institutional Investors Weigh In On Xencor

Several large investors have recently made changes to their positions in the company. Hantz Financial Services Inc. raised its holdings in shares of Xencor by 209.1% during the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 2,156 shares during the last quarter. GAMMA Investing LLC grew its holdings in Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC acquired a new stake in Xencor in the 3rd quarter valued at approximately $44,000. Tower Research Capital LLC TRC increased its position in Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 3,018 shares during the period. Finally, Federated Hermes Inc. raised its stake in Xencor by 114.3% during the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 2,105 shares in the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.